For a compound that still has a devoted following, adrafinil has a surprisingly quiet ending as an official medicine. There was no dramatic recall, no headline safety scandal, no regulator pulling it from shelves. Instead, its manufacturer simply stopped making it, and a drug that had been prescribed in France for a quarter century faded out of the pharmacopoeia in 2011.
Understanding why requires looking at business logic as much as pharmacology. Adrafinil was discontinued because it had become a worse version of a product the same company already sold, because its safety profile gave regulators and the manufacturer no reason to defend it, and because its commercial value had collapsed. This article works through each of those threads, and then considers what the discontinuation does and does not mean for people who still use adrafinil today.
A Short Timeline
- 1974: Chemists at Laboratoires Lafon in France synthesize adrafinil (compound code CRL-40028) while screening sulfinyl compounds for CNS activity.
- Late 1970s: Lafon identifies modafinil (CRL-40476) as the active metabolite responsible for adrafinil’s wakefulness effect.
- 1985: Adrafinil is approved in France as Olmifon, indicated for vigilance and attention problems, particularly in elderly patients.
- 1994: Modafinil is approved in France as Modiodal.
- 1998: Modafinil receives FDA approval in the US as Provigil, licensed by Cephalon.
- 2001: Cephalon acquires Lafon, bringing adrafinil and modafinil under one owner.
- 2007: Armodafinil (Nuvigil), the R-enantiomer of modafinil, is approved in the US.
- 2011: Cephalon discontinues Olmifon. In the same year, Cephalon itself is acquired by Teva.
The dates tell most of the story. Adrafinil was only ever marketed for the sixteen years between its approval and the arrival of its own metabolite as a stand-alone drug, and then lingered for another seventeen years as a legacy product before being shut down.
Reason One: It Was Made Redundant by Modafinil
The deepest reason for the discontinuation is pharmacological. Adrafinil is a prodrug. On its own it does very little; the wakefulness effect comes from modafinil, which the liver produces by cleaving off adrafinil‘s hydroxamic acid group.
Once Lafon isolated modafinil and confirmed it could be given directly, adrafinil’s rationale weakened considerably. Compare the two:
| Property | Adrafinil (Olmifon) | Modafinil (Modiodal / Provigil) |
| Dose for equivalent effect | 300–600 mg | 100–200 mg |
| Onset | 60–120 minutes | 30–60 minutes |
| Bioavailability of active compound | Variable, depends on liver conversion | Direct |
| Metabolic byproducts | Modafinil plus large amounts of modafinilic acid | Modafinilic acid, modafinil sulfone |
| Liver burden | Higher | Lower |
| Dose consistency between patients | Lower | Higher |
Every row favors modafinil. A drug company holding both molecules had no clinical argument for continuing to promote the older one, and every argument for steering prescribers toward the newer one, which also happened to be patent-protected and approved in the far larger US market.
The enantiomer refinement
The redundancy deepened in 2007 when Cephalon launched armodafinil, the purified R-enantiomer of modafinil with a half-life of around 15 hours and a smoother, longer curve. By that point the company had three generations of the same mechanism. The oldest, least precise generation was the obvious one to retire.
Reason Two: The Liver Question
Adrafinil was never withdrawn for safety reasons in the formal sense; there was no regulatory action. But its safety profile contributed to the decision in two ways.
First, its prescribing information had long recommended monitoring liver function in patients on extended treatment, because a subset of users developed elevated hepatic enzymes. The mechanism is straightforward: the liver has to process a large mass of compound to yield a small amount of active drug, and it does so through enzyme systems that respond to chronic load. Modafinil is not entirely free of liver considerations, but it removes the conversion step and the associated burden.
Second, adrafinil’s target population, elderly patients with low vigilance, was exactly the group most likely to have reduced hepatic reserve and to be taking other medications. That made the liver monitoring requirement a practical nuisance for prescribers, and it made the product’s risk-benefit balance look poor next to a cleaner alternative.
A company deciding whether to keep manufacturing a low-revenue drug with a known monitoring requirement, when it already sells a higher-revenue drug without that requirement, has an easy decision.
Reason Three: Commercial Irrelevance
Olmifon was never a large product. Its indication was narrow and somewhat vaguely defined, it was approved in only one major market, and it was generic in nature by the 2000s, with no patent protection worth defending. Meanwhile, Provigil became a blockbuster, generating well over a billion dollars a year at its peak in the US alone, driven partly by off-label prescribing for fatigue, ADHD, and depression.
From Cephalon’s perspective:
- Olmifon revenue was negligible next to Provigil and Nuvigil
- Maintaining a separate manufacturing line, regulatory dossier, and pharmacovigilance program for it cost money
- Any adverse event attributed to adrafinil could reflect on the modafinil franchise, since the two were so closely linked
- The company was in the middle of preparing for Provigil’s patent expiry and shifting patients to Nuvigil, and had no reason to spend resources on a legacy prodrug
Discontinuing Olmifon was a routine portfolio decision, the kind pharmaceutical companies make every year with old products that no longer justify their overhead.
Reason Four: Regulatory Drift
Adrafinil’s regulatory footing had also eroded. French drug regulation tightened considerably through the 2000s, particularly after several high-profile safety controversies involving older drugs with weak efficacy evidence. Regulators began reassessing medicines that had been approved decades earlier under less demanding standards.
Olmifon’s original efficacy data consisted of small, mostly French-language trials from the 1980s in a loosely defined patient population. That evidence base would not have satisfied a modern approval, and a re-evaluation would likely have required new trials the manufacturer had no interest in funding. Voluntary discontinuation avoided that entirely.
What Discontinuation Did Not Mean
It is worth being precise about what happened, because the discontinuation is sometimes misdescribed.
It was not a ban. No country prohibited adrafinil in response to the discontinuation. Its legal status in most places was, and remains, unscheduled and unapproved.
It was not a recall. Existing stock was not pulled from pharmacies for a safety reason; it simply sold through.
It was not a finding of danger. The liver concern was known throughout the product’s life, documented in its labeling, and considered manageable with monitoring. The discontinuation reflected relative disadvantage, not an acute hazard.
It did not eliminate the compound. Because adrafinil is a simple molecule that is off-patent, chemical manufacturers, mainly in China and India, continued to produce it, and gray-market vendors continued to sell it as a research chemical or supplement ingredient.
How the nootropic market picked it up
The discontinuation actually increased adrafinil’s visibility in one specific community. Modafinil was prescription-only and Schedule IV in the US; adrafinil was neither. As modafinil’s reputation as a “smart drug” grew through the 2000s and 2010s, people who could not get a prescription looked for alternatives, and a discontinued, unscheduled prodrug that the body converts into the drug they wanted was an obvious candidate. For a decade it was one of the most popular entries in the nootropic catalog, sold with no pharmaceutical oversight to a population, healthy adults, that the original clinical data had never studied.
What the Discontinuation Means for Users Today
The reasons adrafinil was retired are exactly the reasons to be thoughtful about using it now.
Quality is unregulated. There is no manufacturer standing behind a batch, no pharmacovigilance system, no batch-recall mechanism. Purity and potency depend entirely on the chemical supplier and the vendor, and testing is voluntary.
The liver concern applies to you. The monitoring guidance written for French prescription patients applies at least as much to healthy adults self-dosing without any medical oversight. Regular users should get periodic liver panels.
Dose needs are higher and less predictable. The conversion step means variable results from person to person and day to day, which was one of the original arguments against the drug.
The alternative it was replaced by is now widely available. Generic modafinil and armodafinil are inexpensive, manufactured under regulatory oversight, and sold over the counter or with minimal restriction in a number of countries. Many people who start with adrafinil for legal or accessibility reasons eventually move to the direct-acting mental performance enhancer that replaced it, which is, after all, the same conclusion its original manufacturer reached.
Prescription rules for these compounds vary from country to country, none of them replace adequate sleep, and anyone with liver disease or on other medications should talk with a doctor before using any eugeroic.
Frequently Asked Questions
Did adrafinil cause a specific safety incident that led to withdrawal? No. There was no cluster of serious adverse events, no regulatory action, and no public warning associated with the discontinuation. The liver-enzyme issue was long-known and documented in the label.
Why did Cephalon keep selling it for ten years after acquiring Lafon? Discontinuing a licensed product involves regulatory paperwork and transition planning for existing patients. It was likely simpler to let a small, stable product continue until a convenient moment, which arrived during the Teva acquisition period in 2011.
Is adrafinil still made anywhere as a medicine? No. There is no licensed pharmaceutical manufacturer of adrafinil today. All available product is from chemical suppliers and is not produced under drug-manufacturing standards.
Could adrafinil come back as an approved drug? It is very unlikely. There is no patent value, the market is fully served by modafinil and armodafinil, and any new approval would require modern trials demonstrating an advantage that the compound does not have.
Does discontinuation mean adrafinil is dangerous? It means adrafinil is inferior to its metabolite in most respects and carries an additional liver consideration. For occasional, low-dose use in a healthy adult it is generally well tolerated. It was retired for being obsolete, not for being acutely hazardous.
Final Thoughts
Adrafinil was discontinued for the most ordinary of pharmaceutical reasons: it was superseded. The company that owned it had discovered that the body turns it into a better drug, developed that better drug into a blockbuster, refined it further into a single-enantiomer version, and eventually saw no reason to keep making the original. The liver monitoring requirement, the thin efficacy data, and the negligible revenue simply confirmed a decision that pharmacology had already made.
For today’s users, the lesson is not that adrafinil is unsafe, but that it is a rough draft. It works because it becomes modafinil, and it carries burdens that modafinil does not. If you use it, use it with that history in mind: modest doses, occasional use, attention to the liver, and a clear-eyed sense that the manufacturer’s replacement for it exists for good reasons.
For more topic guides and related resources, visit Modavance.
